People | February 24, 2023
The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies
There is a fast resurgence in the transplant activities post COVID
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
Themis will market this drug with the brand name REMITHEM.
The company has launched its new range of 25 allopathy ophthalmic products including GUERIMOD, GUERIPRED, BIMATO MST etc. for curing various diseases related to eyes
The company has reported total income of Rs. 701 crores during the period ended December 31, 2022
She is a seasoned leader with nearly 30 years of business leadership and consulting experience with top companies such as Mckinsey and Co, Novartis Pharmaceuticals and Stryker India Pvt. Ltd.
Technology and innovation play a pivotal role towards enhancing healthcare systems, increasing access to healthcare services, and reducing costs of therapies and consultations
A pharma industry veteran with over three decades of experience in domestic as well as international markets
Subscribe To Our Newsletter & Stay Updated
